布美他尼联合阿魏酸哌嗪对慢性肾小球肾炎患者临床指标的影响  

Effect of Bumetanide Combined with Piperazine Ferulate on Clinical Indicators in Patients with Chronic Glomerulonephritis

作　　者：杜艳彬 杜艳玲 赖诚民 熊娟 Du Yanbin;Du Yanling;Lai Chengmin;Xiong Juan(Department of General Medicine,Nanchong Central Hospital,Nanchong 637000,China;Health Management Center,Nanchong Central Hospital,Nanchong 637000,China)

机构地区：[1]南充市中心医院全科医学科,南充637000 [2]南充市中心医院健康管理中心,南充637000

出　　处：《成都医学院学报》2024年第3期476-479,共4页Journal of Chengdu Medical College

基　　金：四川省南充市科技局科技项目(No:22SXQT0135)。

摘　　要：目的 探究布美他尼联合阿魏酸哌嗪对慢性肾小球肾炎(CGN)患者临床指标的影响。方法 选取2020年6月至2022年6月南充市中心医院CGN患者120例作为研究对象,采用随机数字表法将患者分为试验组(采用布美他尼+阿魏酸哌嗪治疗)和对照组(采用阿魏酸哌嗪治疗),每组60例。比较两组患者的临床疗效、炎症指标、肾纤维化和肾功能指标、24 h尿蛋白水平和不良反应发生率。结果 试验组临床疗效(96.67%)明显高于对照组(83.33%)(P<0.05);与治疗前比较,治疗后两组白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、凝血酶激活纤溶抑制物(TAFI)均有所降低,与对照组比较,试验组治疗后IL-6、TNF-α、TAFI水平更低(P<0.05);与治疗前比较,治疗后两组纤维连接蛋白(FN)、转化生长因子β1(TGF-β1)、金属蛋白酶组织抑制因子1(TIMP-1)等肾纤维化指标和血尿素氮(BUN)、血清肌酐(SCR)等肾功能指标均下降,与对照组比较,试验组治疗后肾纤维化、肾功能指标更低(P<0.05);两组治疗后红细胞、白细胞计数、24 h尿蛋白均下降,且试验组尿常规相关指标水平更低(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论 布美他尼联合阿魏酸哌嗪能有效降低CGN患者的尿蛋白、血清TAFI水平和肾纤维化水平,改善肾脏功能。Objective To explore the effect of bumetanide combined with piperazine ferulate on clinical indicators in patients with chronic glomerulonephritis(CGN).Methods A total of 120 CGN patients in Nanchong Central Hospital from June 2020 to June 2022 were selected as the study objects.They were divided into an experimental group(n=60,treated with bumetanide and piperazine ferulate)and a control group(n=60,treated with piperazine ferulate)by random number table method.The clinical efficacy,inflammatory indexes,renal fibrosis and renal function indexes,24 h urinary protein levels and incidence of adverse reactions were compared between the two groups.Results The clinical effect in the experimental group(96.67%)was significantly higher than that in the control group(83.33%)(P<0.05).Serum levels of interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and thrombine-activated fibrinolytic inhibitor(TAFI)were decreased in both groups after treatment,and those in the experimental group were significantly lower than those in the control group(P<0.05).After treatment,renal fibrosis indexes such as fibronectin(FN),transforming growth factorβ1(TGF-β1)and tissue inhibitor of metalloproteinase 1(TIMP-1)and renal function indexes such as blood urea nitrogen(BUN)and serum creatinine(SCR)were decreased in both groups,and those in the experimental group were significantly lower than those in the control group(P<0.05).Urine routine indexes such as red blood cell count,white blood cell count and 24 h urinary protein were decreased in both groups after treatment,and those in the experimental group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Bumetanide combined with piperazine ferulate can effectively reduce the levels of urinary protein and serum TAFI,inhibit renal fibrosis and improve renal function in the treatment of patients with CGN.

关 键 词：布美他尼 阿魏酸哌嗪 慢性肾小球肾炎 尿蛋白 肾纤维化 血清纤溶抑制物水平 

分 类 号：R692.31[医药卫生—泌尿科学] R914[医药卫生—外科学]